

REVIEW

Open Access



Abdominal obesity and metabolic syndrome: exercise as medicine?

Carole A. Paley^{1,2*} and Mark I. Johnson²

Abstract

Background: Metabolic syndrome is defined as a cluster of at least three out of five clinical risk factors: abdominal (visceral) obesity, hypertension, elevated serum triglycerides, low serum high-density lipoprotein (HDL) and insulin resistance. It is estimated to affect over 20% of the global adult population. Abdominal (visceral) obesity is thought to be the predominant risk factor for metabolic syndrome and as predictions estimate that 50% of adults will be classified as obese by 2030 it is likely that metabolic syndrome will be a significant problem for health services and a drain on health economies.

Evidence shows that regular and consistent exercise reduces abdominal obesity and results in favourable changes in body composition. It has therefore been suggested that exercise is a medicine in its own right and should be prescribed as such.

Purpose of this review: This review provides a summary of the current evidence on the pathophysiology of dysfunctional adipose tissue (adiposopathy). It describes the relationship of adiposopathy to metabolic syndrome and how exercise may mediate these processes, and evaluates current evidence on the clinical efficacy of exercise in the management of abdominal obesity. The review also discusses the type and dose of exercise needed for optimal improvements in health status in relation to the available evidence and considers the difficulty in achieving adherence to exercise programmes.

Conclusion: There is moderate evidence supporting the use of programmes of exercise to reverse metabolic syndrome although at present the optimal dose and type of exercise is unknown. The main challenge for health care professionals is how to motivate individuals to participate and adherence to programmes of exercise used prophylactically and as a treatment for metabolic syndrome.

Keywords: Metabolic syndrome, Exercise medicine, Abdominal obesity, Adiposopathy

Background

Metabolic syndrome is defined as a cluster of at least three out of five clinical risk factors: abdominal (visceral) obesity, hypertension, elevated serum triglycerides, low serum high-density lipoprotein (HDL) and insulin resistance [1]. The prevalence of metabolic syndrome has been estimated to be more than 20% of the global adult population [2, 3]. Of the five clinical risk factors used as diagnostic criteria for metabolic syndrome, abdominal obesity appears to be the most predominant [3, 4]. Obesity is defined as a body mass index (BMI) of 30 or

above and has been described as a global pandemic with approximately 50% of adults worldwide expected to be obese by 2030 [5]. Abdominal (visceral) obesity, irrespective of other fat deposits, is a major risk factor for systemic inflammation, hyperlipidaemia, insulin resistance and cardiovascular disease (for review, see [6]). The role of abdominal obesity in the development of insulin resistance and the metabolic syndrome was described in 1991 [7]. However, abdominal obesity does not always occur in individuals with an elevated BMI. It was recognised as early as 1981 that normal weight, metabolically obese, individuals existed due to the presence of excessive visceral fat deposits [8].

Evidence shows that one of the single most important lifestyle changes for the prevention of many chronic diseases is exercise [9] and as a consequence exercise is

* Correspondence: carole.paley@anhst.nhs.uk

¹Research & Development (Ward 12), Airedale NHS Foundation Trust, Skipton Road, Steeton, Keighley, West Yorkshire BD20 6TD, UK

²School of Clinical and Applied Sciences, Leeds Beckett University, Portland Building, City Campus, Leeds LS1 3HE, UK



now recognised as a medical treatment in its own right [6]. There is growing evidence that regular and consistent programmes of exercise will reduce abdominal fat deposits significantly, independent of weight loss [10, 11]. It is recognised that changes in body composition - particularly a reduction in abdominal fat deposits - are more important than reductions in overall body weight, or BMI, in treating metabolic syndrome. Reductions in abdominal fat deposits are important because abdominal obesity is a marker of dysfunctional adipose tissue (adiposopathy) [12]. Abdominal, or visceral obesity has a central role in the development of a pro-inflammatory state which we now know is associated with metabolic syndrome [13]. It has been suggested that exercise as a medical intervention should be prescribed in terms of its dose, i.e. mode, intensity, frequency and duration [14]. This was the basis of the American College of Sports Medicine Exercise is Medicine® (EIM) initiative [15] and their guidance on prescribing exercise [16]. As a medical intervention the prescription for exercise should also be specifically based on the individual's capabilities and needs.

The aim of this review is to (i) summarise current evidence on the pathophysiology of dysfunctional adipose tissue (adiposopathy), its relationship to metabolic syndrome and how exercise may mediate these processes; and (ii) evaluate current evidence on the clinical efficacy of exercise in the management of abdominal obesity and to assess the type and dose of exercise needed for optimal improvements in health status.

Abdominal obesity, adiposopathy and metabolic dysfunction

To understand the significance of abdominal obesity and its contribution to metabolic syndrome, it is necessary to appreciate the link between the diseases associated with this condition. The accumulation of ectopic fat in tissue surrounding the viscera is directly related to the development of insulin resistance [17]. Insulin resistance is thought to be the common denominator in the development of metabolic syndrome. In addition, evidence suggests that systemic inflammation is an important factor in its development, through the development of insulin resistance [18–21]. Visceral fat deposits (abdominal adiposity) are associated with the development of adipose cells that are enlarged and dysfunctional (adiposopathy, or 'sick fat') [21]. Dysfunctional adipose tissue secretes pro-inflammatory biomarkers including prostaglandins, C-reactive protein (CRP), and cytokines such as interleukins (e.g. interleukin-6), tumour necrosis factor alpha (TNF- α), and leptin [22, 23]. With increasing obesity there is also a corresponding decrease in levels of adiponectin, an antiatherosclerotic adipokine [24]. Inflammatory mediators released by adipose tissue contribute to the development of type II diabetes, hyperlipidaemia and

cardiovascular disease [25, 26]. If there is a high proportion of fat to muscle this is likely to contribute to this metabolic dysfunction as an increase in circulation of free fatty acids requires greater insulin secretion for control of glucose metabolism. The resulting hyperinsulinaemia desensitises insulin-sensitive tissues, which predisposes individuals to type II diabetes [27]. The decrease in adiponectin secretion also inhibits insulin receptor proteins. Moreover, regular consumption of foods rich in carbohydrate results in postprandial hyperglycaemia which causes repetitive acute inflammation which might contribute to a chronic inflammatory state [28]. Chronic systemic inflammation increases oxidative stress and reduces metabolic flexibility, thus perpetuating metabolic syndrome, leading to a vicious cycle of disease, depression and further inactivity [29, 30].

Adipose tissue hypoxia also occurs in the obese state although the mechanisms for this are not fully understood [19]. It has been suggested that deficient angiogenesis causes decreased blood flow due to reduction in capillary density and excessive growth of adipose tissue. This may also be exacerbated by obstructive sleep apnoea which is common in obese individuals, and results in a reduction of oxygen to the tissues [31]. Adipose tissue, hypoxia is associated with an increased expression of inflammatory genes and decreased expression of adiponectin, resulting in local and systemic inflammation [19, 32, 33]. The response to adipose tissue hypoxia includes insulin sensitivity and glucose intolerance as adiponectin is associated with normal glucose and lipid metabolism. Leptin expression has also been shown to increase in obesity and the likely explanation for this is adipose tissue hypoxia [34]. This is important as leptin expression modulates insulin resistance [35]. Furthermore, ghrelin regulation in obese individuals is affected and serum ghrelin suppression in response to stomach fullness is impaired which results in a failure to suppress the continued desire to eat, thus compounding the problem [35].

Hypothalamic-pituitary-adrenal (HPA) axis hyperactivity is evident in abdominal obesity and is also associated with insulin resistance due to an increase in cortisol levels [36]. Cortisol, secreted by the adrenal glands, is involved in gluconeogenesis which increases blood sugar as a response to stress. Epidemiological data provide evidence for a significant positive association between increased cortisol levels and the risk of developing type II diabetes and atherosclerosis due to a failure to suppress inflammation [37]. Also, the secretion of low grade inflammatory mediators by adipose tissues may act as an additional chronic stimulus to the activation of the HPA axis which in turn results in increased levels of cortisol secretion, resulting in a positive feedback loop [38].

It is important to note that not all obese patients develop metabolic syndrome and there exists a cohort of metabolically 'healthy' individuals who are obese [39]. At present, there is no explanation for this and it is not known whether these metabolically healthy obese individuals will eventually develop metabolic syndrome and are simply experiencing a delayed-onset of disease [24]. Interestingly, there are also normal weight individuals who are regarded as 'metabolically obese' due to the storage of ectopic fat around the viscera whilst maintaining a normal BMI [40, 41].

When BMI is used as a measure of obesity only a modest association with cardiovascular risk factors is found [18]. However, when abdominal obesity measurements, such as waist circumference or waist:hip ratio are included as a measure of abdominal adiposity a strong association with cardiovascular and metabolic syndrome risk factors is found [42–45].

Metabolic dysfunction and exercise

Abdominal adiposity is a reversible condition and its reduction can have excellent effects in diminishing cardiovascular and metabolic syndrome risk. Evidence from a study by Brooks, et al. demonstrated that increased abdominal obesity was associated with systemic inflammation as measured by high-sensitivity C-reactive protein (hsCRP) [18]. Given the direct link between abdominal obesity and systemic inflammation it is not surprising that even modest reductions in abdominal adipose tissue are accompanied by improvements in metabolic function and reduced cardiovascular risk.

Several studies show a strong association between obesity and physical inactivity [46–48] and that metabolic syndrome is associated with sedentary lifestyle and poor cardiorespiratory fitness [49]. Sedentary behaviour is widely regarded as activity which involves energy expenditure at the level of 1.0–1.5 metabolic equivalent units (METs), which usually involves time sitting or lying down and includes office and computer work and watching television [50]. Edwardson et al. conducted a meta-analysis that found that individuals who spend more time in sedentary behaviours have greater odds of having metabolic syndrome [50]. A prospective study which examined the relationship between sedentary behavior and metabolic syndrome in 930 men found that men with middle and high sedentary behavior had a higher risk of developing metabolic syndrome (65% middle and 76% high level sedentary behaviour respectively), than men who were active [51]. A longitudinal study observing 4840 adults found that improvements in cardio-metabolic factors occurred in overweight and obese individuals with increased levels of physical activity, although the participants were those participating in a health screening programme and were therefore

probably of a higher economic status. At follow-up, there was a statistically significant decrease in non-HDL concentrations of 5.8% (overweight) and 4.6% (obese) relative to baseline, and a decrease in low-density lipoprotein (LDL) cholesterol concentrations of 4.7% (overweight) and 6.1% (obese) relative to baseline [52]. Of the parameters observed, non-HDL cholesterol and plasma triglycerides were found to have the largest improvement when physical activity was increased. A study followed 22,383 participants, aged 30–64 years, comparing metabolic syndrome risk with intensity level of leisure-time exercise and by occupational and commuting activity [53]. Leisure-time activity was found to be linearly and inversely associated with a risk of developing metabolic syndrome and vigorous-intensity activity alone or a combination of both moderate- and vigorous-intensity activity was associated with a lower risk of metabolic syndrome. The researchers classified activity levels according to the MET equivalent: moderate-intensity at 3–6 METs and vigorous-intensity >6 METs. The introduction of increased physical activity into a previously inactive lifestyle might also break the cycle of inflammation-mediated sickness behaviour as described by Nunn, which suppresses the desire to undertake physical activity [30].

A systematic review and meta-analysis was conducted by Ostman et al. 2017 to determine whether exercise reversed various indices of metabolic syndrome including body composition, blood cholesterol, fasting blood glucose, fasting insulin, blood pressure and clinical outcome [54]. A total of 16 studies (800 participants) were included in the review and it was found that aerobic training produced small improvements in fasting blood glucose, triglycerides and low-density lipoproteins. Combined aerobic and resistance exercise training resulted a reduction of 13% in triglycerides only. Nevertheless, combined with improvements in maximal oxygen uptake and blood pressure, the overall risk profile for patients was much improved. When the combined exercise group was compared with the control group the mean difference of: waist circumference was -3.80 cm (95% CI $-5.65, -1.95, p < 0.0001$); systolic blood pressure was -3.79 mmHg (95% CI $-6.18, -1.40, p = 0.002$); and HDL was 0.14 (95% CI $0.04, 0.25, p = 0.009$). The improvements in waist measurement would suggest that the long-term risks associated with metabolic syndrome were reduced. An earlier review to determine the effectiveness of 'lifestyle modification programmes' on improving metabolic risk factors (blood pressure, triglycerides and waist circumference) in adults with metabolic syndrome found reductions in these measures, although such programmes were said to be more effective if carried out for more than 12 weeks, thus emphasising the need for long-term lifestyle modifications [55].

There are a number of studies which have specifically investigated the effect of exercise on abdominal obesity, irrespective of total body weight and these are summarised in a comprehensive review by Pedersen and Saltin [56]. Amongst their findings they reported that a cross-sectional study of overweight males showed that those with a high level of fitness (as measured by activity and maximal oxygen uptake) had lower levels of visceral fat than their unfit counterparts when scanned using magnetic resonance imaging [39]. Lee et al. investigated the effects of exercise without weight loss on total and abdominal adiposity and skeletal muscle mass and composition in previously sedentary, lean men and in obese men with and without type II diabetes [11]. It was found that, even in the absence of weight loss, moderate-intensity exercise was associated with significant reductions in total and abdominal fat, and there was a reduction in skeletal muscle lipid content independent of group. Stewart et al. investigated the effects of exercise on cardiovascular and metabolic disease in older adults and found that reductions in total and abdominal fatness and increase in leanness were strongly associated with reductions in risk factors for cardiovascular disease and diabetes, including those that constitute metabolic syndrome [57]. Lee et al. conducted a longitudinal study of 32,593 adults who underwent an abdominal computerised tomography scan as part of health screening and found that the ratio of visceral-to-subcutaneous fat was independently associated with all-cause mortality. This suggests that the location of fat deposits in the abdomen (viscera) is a better indicator of metabolic risk than total body fat, which is unsurprising given the positive association between abdominal adiposity and systemic inflammation [58].

A number of reviews have shown that exercise training specifically elicits an anti-inflammatory effect, independent of weight loss [33, 59–62]. Other metabolic benefits of exercise were reported in a study on patients with type II diabetes where pedometer-measured exercise was not only associated with reductions in systemic inflammation, but also reductions in abdominal obesity and arterial stiffness [63]. One of the mechanisms for the anti-inflammatory effect of exercise is a reduction in adipose tissue hypoxia resulting from improved capillary density blood flow. In a review by Golbidi [24] the inverse relationship between exercise, body mass index (BMI), hip-waist ratio, and waist circumference was described. The anti-inflammatory effect of exercise was also explained as being closely related to oxidative stress. Exercise was shown to improve glucose tolerance, insulin resistance and lipid metabolism and reduce blood pressure in both healthy individuals and those with metabolic disease. Large population cohort studies observed relationships between plasma CRP and the level of exercise that was independent of obesity as measured

by body mass index [62, 64]. The effect of exercise training on CRP was investigated in a systematic review which considered a total of 83 studies of different types. It was found that exercise training led to a greater reduction in CRP when accompanied by a decrease in BMI, but that significant reductions in CRP occurred without weight loss [65]. Furthermore, a Cochrane review provided evidence that exercise improved general health even where no weight was lost because it improved plasma lipoprotein profile [66].

Not all studies provide evidence that exercise training reduces pro-inflammatory biomarkers. Melo et al. reviewed 11 studies of patients with type II diabetes and found insufficient evidence to determine whether aerobic or resistance exercise improved systemic levels of inflammatory markers [67]. However, an earlier review by Hayashino et al. found that both CRP and IL-6 were reduced by exercise training [68]. It is still unclear whether improvements in inflammatory status are independent of weight loss or entirely dependent upon the changes in body composition that result from exercise training [61]. Nevertheless, Eaton and Eaton observed that the percentage of lean body mass is critical in avoiding the hyperinsulinaemia which predisposes individuals to type II diabetes because a greater insulin secretion is required for any given glucose load where levels of body fat are disproportionate [27]. This would suggest that strength training that develops lean tissue is critical in the treatment, or prevention, of metabolic disease.

Optimal dose of exercise

There are no specific guidelines on exercise prescription for systemic inflammation although guidance is available in the form of programmes designed to reduce body fat and improve general health status. The American College of Sports Medicine (ACSM) recommends 150–250 min of moderate-intensity exercise per week as optimal but other authors have suggested between 30 [69] and 60 [70] minutes per day would be required. There is a consensus that performing 3000 steps (~30 min of activity) per day over and above normal activities is sufficient for improvements in health status but perhaps not optimal according to the ACSM recommendations [71–75]. A systematic review and meta-analysis by Hayashino et al. [68] was conducted to assess the effects of exercise interventions on inflammatory markers/cytokines and adipokines which contribute to the development of atherosclerosis, insulin resistance, and development of late-onset complication in patients with type II diabetes. They found that exercise training with a longer duration and frequency was more effective in reducing systemic inflammation, suggesting that these effects might be dose-dependent. More recently, this idea has been challenged and it is now thought that

shorter-duration, higher intensity interval training (HIIT) is beneficial [76]. Recent findings suggest that HIIT programmes are effective in reducing metabolic syndrome combined with high adherence rates and this is important because incorporating HIIT programmes into daily life is less disruptive. Gremeaux, et al. studied the effects of HIIT training on a sample of 62 overweight or obese adults who were above the recommended abdominal obesity threshold. All participants completed 2–3 weekly sessions of repeated short-duration (15–30 s) interval training at 80% of their aerobic threshold. It was found that the prevalence of metabolic syndrome was reduced by 32.5% at the 9 month follow-up. Importantly, adherence rates to the programme were 97%.

In a study designed to evaluate the effects of different intensity exercise programmes combined with a healthy diet in subjects with metabolic syndrome, 75 non-diabetic subjects were recruited to undertake either a programme of 10,000 steps per day, a fitness programme involving activity at >75% peak $\text{VO}_{(2)}$ three times per week or a 12 week programme of walking 1 h each day [77]. The metabolic and vascular effects of these three different regimens were studied and improvements were observed in various measures including BMI, waist measurement, glucose metabolism, insulin resistance and lipid profiles. The more intense exercise regimen at >75% peak $\text{VO}_{(2)}$, combined with a low-sugar diet, was most effective, which provides further support to the evidence showing the benefits of HIIT training in combination with dietary advice. A significant observation was that in 64% of the study participants metabolic syndrome was resolved.

Zhang et al. also found that high intensity interval training was better than continuous moderate aerobic training in reducing abdominal visceral fat in obese young women [78]. Similar findings from other studies support the benefit of high-intensity interval training performed in short, high-intensity bursts, involving as little as 10 min of activity at a time, and this might promote better adherence in non-habitual exercisers [79–81]. A further study of 2330 adults found that consistent moderate to vigorous activity was more important than exercise volume in reducing CRP levels associated with systemic inflammation [82]. A systematic review by Cronin et al. found that greater reductions in inflammatory biomarkers occurred in older healthy inactive participants when higher intensity aerobic exercise was undertaken [83].

A review by Zdziarski et al. found that largest reductions in systemic inflammation and improvements in well-being, depression and sleep was achieved using multi-modal exercise (aerobic and resistance training) in individuals with inflammation-related chronic pain [84]. This is important because it is likely that individuals in a pro-inflammatory state due to abdominal adiposopathy

may also be susceptible to chronic pain conditions. Dutheil et al. reported that high resistance-moderate endurance training was efficient in improving visceral fat loss in 100 healthy adults [85]. If changes in body composition are more important than total body weight loss then resistance training combined with aerobic exercise would produce optimal effects in increasing percentage lean body mass [27].

Promoting adherence to exercise Programmes

One of the major challenges in using programmes of exercise to improve health status is promoting and maintaining adherence in individuals who have often been inactive for many years and who may be overweight or obese [86]. Ideally, therefore, attempts should be made to include exercise into normal daily life although attrition rates can still be as high as 50% [87]. To promote adherence Clauw and Crofford suggested that additional activity is incorporated very gradually – as little as 5 min daily [88] although the programme needs to be tailored to the individual whilst aiming to deliver optimal effects [84]. As discussed above, the recent findings that HIIT programmes are effective in reducing metabolic syndrome combined with high adherence rates is significant because incorporating it into daily life is less disruptive. Connelly et al. conducted a review to assess the effectiveness of technology to promote physical activity in people with Type 2 diabetes and found that the use of technology-based interventions, such as mobile phone applications, texts and email support, improves compliance [89].

In summary, evidence suggests that optimal abdominal fat reduction and the development of lean tissue is achieved by combining high-intensity interval training and resistance training with an overall general increase in daily physical activity.

Conclusion

An increasingly sedentary lifestyle, a lack of regular exercise and an increase in obesity have been the main contributors to a rise in the incidence of metabolic dysfunction, particularly in the developed world. There is moderate evidence supporting the use of programmes of exercise to reverse metabolic syndrome although at present the optimal dose and type of exercise is unknown. The main challenge for health care professionals is how to motivate individuals to participate and adherence to programmes of exercise used prophylactically and as a treatment for metabolic syndrome.

Abbreviations

ACSM: American College of Sports Medicine; BMI: Body mass index; CRP: C-reactive protein; EIM: Exercise is Medicine; HDL: High density lipoprotein; HIIT: High Intensity Interval Training; HPA: Hypothalamic-pituitary-adrenal; hsCRP: High-sensitivity C-reactive protein; LDL: Low density lipoprotein; METS: Metabolic equivalent units; TNF- α : Tumour necrosis factor alpha; $\text{VO}_{(2)}$: Oxygen Uptake

Funding

The production of this review was not funded by any source.

Author contributions

CP was responsible for collating the required information for the review, drafting the initial review and writing the final report. MJ was responsible for providing explanation of the physiology, for assisting with the synthesis of information gathered and the writing of the final draft. Both authors read and approved the final manuscript.

Competing interests

The authors have no competing interests to declare.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 15 January 2018 Accepted: 26 April 2018

Published online: 04 May 2018

References

1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. *Circulation*. 2009;120(16):1640–5. <https://doi.org/10.1161/CIRCULATIONAHA.109.192644>.
2. Shin J-A, Lee J-H, Lim S-Y, Ha H-S, Kwon H-S, Park Y-M, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. *Journal Of Diabetes Investigation*. 2013;4(4):334–43. <https://doi.org/10.1111/jdi.12075>.
3. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and nutrition examination survey, 1988–1994. *Arch Intern Med*. 2003;163(4):427–36.
4. Fujita T. Insulin resistance and salt-sensitive hypertension in metabolic syndrome. *Nephrol Dial Transplant*. 2007;22(11):3102–7.
5. WHO. Obesity and overweight. In: Factsheet: WHO; 2014. <http://www.who.int/mediacentre/factsheets/fs311/en/>. Accessed September 2017.
6. Pedersen BK, Saltin B. Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand J Med Sci Sports*. 2015;25:1–72. <https://doi.org/10.1111/sms.12581>.
7. Björntorp P. Metabolic implications of body fat distribution. *Diabetes Care*. 1991;14(12):1132–43. <https://doi.org/10.2337/diacare.14.12.1132>.
8. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese," normal-weight individual. *Am J Clin Nutr*. 1981;34(8):1617–21.
9. Cardinal BJ, Park EA, Kim M, Cardinal MK. If exercise is medicine, where is exercise in medicine? Review of U.S. medical education curricula for physical activity-related content. *J Phys Act Health*. 2015;12(9):1336–43. <https://doi.org/10.1123/jpah.2014-0316>.
10. Davidson LE, Hudson R, Kilpatrick K, Kuk JL, McMillan K, Janiszewski PM, et al. Effects of exercise modality on insulin resistance and functional limitation in older adults: a randomized controlled trial. *Arch Intern Med*. 2009;169(2):122–31. <https://doi.org/10.1001/archinternmed.2008.558>.
11. Lee S, Kuk JL, Davidson LE, Hudson R, Kilpatrick K, Graham TE, et al. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without Type 2 diabetes. *J Appl Physiol* (1985). 2005; 99(3):1220–5.
12. Després J-P, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. *Arterioscler Thromb Vasc Biol*. 2008;28(6):1039–49. <https://doi.org/10.1161/ATVBAHA.107.159228>.
13. Ritchie SA, Connell JMC. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. *Nutr Metab Cardiovasc Dis*. 2007; 17(4):319–26.
14. Swisher AK. Yes, "Exercise is Medicine" ...but It Is So Much More. *Cardiopulm Phys Ther J*. 2010;21(4):4.
15. ACSM. Exercise is Medicine (EIM). American College of Sports Medicine. 2007. <http://www.exerciseismedicine.org/>. Accessed 13/10/2017.
16. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc*. 2011;43(7):1334–59. <https://doi.org/10.1249/MSS.0b013e318213febf>.
17. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Postano V, Buzzigoli E, et al. Visceral fat in hypertension. Influence on Insulin Resistance and β -Cell Function. 2004; 44(2):127–33. <https://doi.org/10.1161/01.HYP.0000137982.10191.0a>.
18. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. *Am J Cardiol*. 2010;106(1):56–61. <https://doi.org/10.1016/j.amjcard.2010.02.017>.
19. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. *Int J Obes* (2005). 2009;33(1):54–66. <https://doi.org/10.1038/ijo.2008.229>.
20. Ryan AS, Ge S, Blumenthal JB, Serra MC, Prior SJ, Goldberg AP. Aerobic exercise and weight loss reduce vascular markers of inflammation and improve insulin sensitivity in obese women. *J Am Geriatr Soc*. 2014;62(4):607–14. <https://doi.org/10.1111/jgs.12749>.
21. Huth C, Pigeon É, Riou M-È, St-Onge J, Arguin H, Couillard E, et al. Fitness, adiposity, and adiposity are independent predictors of insulin sensitivity in middle-aged men without diabetes. *J Physiol Biochem*. 2016;72(3):435–44. <https://doi.org/10.1007/s13105-016-0488-2>.
22. Ellulu MS, Khaza'i H, Rahmat A, Patimah I, Abed Y. Obesity can predict and promote systemic inflammation in healthy adults. *Int J Cardiol*. 2016;215:318–24. <https://doi.org/10.1016/j.ijcard.2016.04.089>.
23. Das UN. Is obesity an inflammatory condition. *Nutrition* (Burbank, Los Angeles County, Calif). 2001;17(11–12):953–66.
24. Golbidi S, Mesdaghinia A, Laher I. Exercise in the metabolic syndrome. *Oxidative Med Cell Longev*. 2012;2012:349710. <https://doi.org/10.1155/2012/349710>.
25. Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. *Interdiscip Top Gerontol*. 2015;40:99–106. <https://doi.org/10.1159/000364934>.
26. Marsland AL, McCaffery JM, Muldoon MF, Manuck SB. Systemic inflammation and the metabolic syndrome among middle-aged community volunteers. *Metab Clin Exp*. 2010;59(12):1801–8. <https://doi.org/10.1016/j.metabol.2010.05.015>.
27. Eaton SB, Eaton SB. Physical inactivity, obesity, and type 2 diabetes: an evolutionary perspective. *Res Q Exerc Sport*. 2017;88(1):1–8. <https://doi.org/10.1080/02701367.2016.1268519>.
28. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation*. 2002;106(16):2067–72.
29. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci*. 2008;9(1):46–56.
30. Nunn AV, Guy GW, Brodie JS, Bell JD. Inflammatory modulation of exercise salience: using hormesis to return to a healthy lifestyle. *Nutr Metab (Lond)*. 2010;7:87. <https://doi.org/10.1186/1743-7075-7-87>.
31. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. *Chest*. 2010;137(3):711–9. <https://doi.org/10.1378/chest.09-0360>.
32. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of Ob/Ob and dietary obese mice. *Am J Physiol Endocrinol Metab*. 2007;293(4):E1118–E28.
33. You T, Arsenis NC, Disanzo BL, Lamonte MJ. Effects of exercise training on chronic inflammation in obesity: current evidence and potential mechanisms. *Sports Medicine* (Auckland, NZ). 2013;43(4):243–56. <https://doi.org/10.1007/s40279-013-0023-3>.
34. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. *Physiol Rev*. 2013;93(1):1–21. <https://doi.org/10.1152/physrev.00017.2012>.
35. Wang T-N, Chang W-T, Chiu Y-W, Lee C-Y, Lin K-D, Cheng YY, et al. Relationships between changes in leptin and insulin resistance levels in obese individuals following weight loss. *Kaohsiung J Med Sci*. 2013;29(8):436–43. <https://doi.org/10.1016/j.kjms.2012.08.041>.
36. Prpic-Križevac I, Canecki-Varžić S, Bilic-Curčić I. Hyperactivity of the hypothalamic-pituitary-adrenal axis in patients with type 2 diabetes and relations with insulin resistance and chronic complications. *Wien Klin Wochenschr*. 2012;124(11):403–11. <https://doi.org/10.1007/s00508-012-0191-4>.

37. Nijm J, Jonasson L. Inflammation and cortisol response in coronary artery disease. *Ann Med*. 2009;41(3):224–33. <https://doi.org/10.1080/07853890802508934>.
38. Tsigos C, Kyrou I. Stress, Insulin Resistance, and Type II Diabetes A2 - Fink, George. *Encyclopedia of Stress* (Second Edition). New York: Academic Press; 2007. p. 654–9.
39. O'Donovan G, Thomas EL, McCarthy JP, Fitzpatrick J, Durighel G, Mehta S, et al. Fat distribution in men of different waist girth, fitness level and exercise habit. *Int J Obes (Lond)*. 2009;33(12):1356–62. <https://doi.org/10.1038/ijo.2009.189>.
40. Sharma S, Batsis JA, Coutinho T, Somers VK, Hodge DO, Carter RE, et al. Normal-weight central obesity and mortality risk in older adults with coronary artery disease. *Mayo Clin Proc*. 2016;91(3):343–51. <https://doi.org/10.1016/j.mayocp.2015.12.007>.
41. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: implications for Total and cardiovascular mortality. *Ann Intern Med*. 2015;163(11):827–35. <https://doi.org/10.7326/M14-2525>.
42. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. *Obes Rev*. 2011;12(9):680–7. <https://doi.org/10.1111/j.1467-789X.2011.00879.x>.
43. Vakili KP, Malhotra S, Sawada S, Campbell SR, Sayfo S, Kamalesh M. Waist circumference and metabolic syndrome: the risk for silent coronary artery disease in males. *Metab Syndr Relat Disord*. 2012;10(3):225–31. <https://doi.org/10.1089/met.2011.0099>.
44. Nazare J-A, Smith J, Borel A-L, Aschner P, Barter P, Van Gaal L, et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). *Am J Cardiol*. 2015;115(3):307–15. <https://doi.org/10.1016/j.amjcard.2014.10.039>.
45. Kartheuser AH, Leonard DF, Penninx F, Paterson HM, Brandt D, Remue C, et al. Waist circumference and waist/hip ratio are better predictive risk factors for mortality and morbidity after colorectal surgery than body mass index and body surface area. *Ann Surg*. 2013;258(5):722–30. <https://doi.org/10.1097/SLA.0b013e3182a6605a>.
46. Telford RD. Low physical activity and obesity: causes of chronic disease or simply predictors? *Med Sci Sports Exerc*. 2007;39(8):1233–40.
47. Bullock VE, Griffiths P, Sherar LB, Clemes SA. Sitting time and obesity in a sample of adults from Europe and the USA. *Ann Hum Biol*. 2017;44(3):230–6. <https://doi.org/10.1080/03014460.2016.1232749>.
48. Roda C, Charreire H, Feuillet T, Mackenbach JD, Compennolle S, Glonti K, et al. Lifestyle correlates of overweight in adults: a hierarchical approach (the SPOTLIGHT project). *Int J Behav Nutr Phys Act*. 2016;13(1):114.
49. Lakka TA, Laaksonen DE, Lakka HM, Mannikko N, Niskanen LK, Rauramaa R, et al. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. *Med Sci Sports Exerc*. 2003;35(8):1279–86. <https://doi.org/10.1249/01.mss.00000079076.74931.9a>.
50. Edwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, et al. Association of sedentary behaviour with metabolic syndrome: a meta-analysis. *Plos One*. 2012;7(4):e34916-e. <https://doi.org/10.1371/journal.pone.0034916>.
51. Greer AE, Sui X, Maslow AL, Greer BK, Blair SN. The effects of sedentary behavior on metabolic syndrome independent of physical activity and cardiorespiratory fitness. *J Phys Act Health*. 2015;12(1):68–73. <https://doi.org/10.1123/jpah.2013-0186>.
52. Ritti-Dias RM, Cucato GG, Do Prado WL, RDO C, Santos RD, Bittencourt MS. Self-initiated changes in physical activity levels improve cardiometabolic profiles: a longitudinal follow-up study. *Nutr Metab Cardiovasc Dis*. 2017; 27(1):48–53. <https://doi.org/10.1016/j.numecd.2016.10.007>.
53. Kuwahara K, Honda T, Nakagawa T, Yamamoto S, Akter S, Hayashi T, et al. Leisure-time exercise, physical activity during work and commuting, and risk of metabolic syndrome. *Endocrine*. 2016;53(3):710–21. <https://doi.org/10.1007/s12020-016-0911-z>.
54. Ostman C, Smart NA, Morcos D, Duller A, Ridley W, Jewiss D. The effect of exercise training on clinical outcomes in patients with the metabolic syndrome: a systematic review and meta-analysis. *Cardiovascular Diabetology*. 2017;16(1):110. <https://doi.org/10.1186/s12933-017-0590-y>.
55. Lin C-H, Chiang S-L, Tzeng W-C, Chiang L-C. Systematic review of impact of lifestyle-modification programs on metabolic risks and patient-reported outcomes in adults with metabolic syndrome. *Worldviews Evid-Based Nurs*. 2014;11(6):361–8. <https://doi.org/10.1111/wvn.12069>.
56. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand J Med Sci Sports*. 2015;25(Suppl 3):1–72. <https://doi.org/10.1111/sms.12581>.
57. Stewart KJ, Bacher AC, Turner K, Lim JG, Hees PS, Shapiro EP, et al. Exercise and risk factors associated with metabolic syndrome in older adults. *Am J Prev Med*. 28(1):9–18. <https://doi.org/10.1016/j.amepre.2004.09.006>.
58. Lee SW, Son JY, Kim JM, Hwang S-S, Han JS, Heo NJ. Body fat distribution is more predictive of all-cause mortality than overall adiposity. *Obesity & Metabolism: Diabetes*; 2017. <https://doi.org/10.1111/dom.13050>.
59. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. *J Am Coll Cardiol*. 2005;45(10):1563–9.
60. Vella CA, Allison MA, Cushman M, Jenny NS, Miles MP, Larsen B, et al. Physical activity and adiposity-related inflammation: the MESA. *Med Sci Sports Exerc*. 2017;49(5):915–21. <https://doi.org/10.1249/MSS.0000000000001179>.
61. Wärnberg J, Cunningham K, Romeo J, Marcos A. Physical activity, exercise and low-grade systemic inflammation. *Proc Nutr Soc*. 2010;69(3):400–6. <https://doi.org/10.1017/s0029665110001928>.
62. Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. *CMAJ: Canadian Medical Association Journal = Journal De L'association Medicale Canadienne*. 2005;172(9):1199–209.
63. Jennersjö P, Ludvigsson J, Länne T, Nyström FH, Ernerudh J, Östgren CJ. Pedometer-determined physical activity is linked to low systemic inflammation and low arterial stiffness in type 2 diabetes. *Diabetic Medicine: A Journal Of The British Diabetic Association*. 2012;29(9):1119–25. <https://doi.org/10.1111/j.1464-5491.2012.03621.x>.
64. Bergström G, Behre CJ, Schmidt C. Moderate intensities of leisure-time physical activity are associated with lower levels of high-sensitivity C-reactive protein in healthy middle-aged men. *Angiology*. 2012;63(6):412–5. <https://doi.org/10.1177/0003319711423386>.
65. Fedewa MV, Hathaway ED, Ward-Ritacco CL. Effect of exercise training on C reactive protein: a systematic review and meta-analysis of randomised and non-randomised controlled trials. *British Journal Of Sports Medicine*. 2017; 51(8):670–6. <https://doi.org/10.1136/bjsports-2016-095999>.
66. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. *The Cochrane Database Of Systematic Reviews*. 2009;4:CD003817.
67. Melo LC, Dativo-Medeiros J, Menezes-Silva CE, Barbosa FT, de Sousa-Rodrigues CF, Rabelo LA. Physical Exercise on Inflammatory Markers in Type 2 Diabetes Patients: A Systematic Review of Randomized Controlled Trials. *Oxid Med Cell Longev*. 2017;2017:8523728. <https://doi.org/10.1155/2017/8523728>.
68. Hayashino Y, Jackson JL, Hirata T, Fukumori N, Nakamura F, Fukuhara S, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. *Metab Clin Exp*. 2014;63(3):431–40. <https://doi.org/10.1016/j.metabol.2013.08.018>.
69. Wareham N, van Sluijs E, Ekelund U. Physical activity and obesity prevention: a review. *Proc Nutr Soc*. 2005;64:229–47.
70. Slentz CA, Duscha BD, Johnson JL, Ketchum K, Aiken LB, Samsa GP, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE—a randomized controlled study. *Arch Intern Med*. 2004;164(1):31–9.
71. Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M et al. Translating Physical Activity Recommendations into a Pedometer-Based Step Goal: 3000 Steps in 30 Minutes. *Am J Prev Med*. 2009;36(5):410–15. doi:<https://doi.org/10.1016/j.amepre.2009.01.021>.
72. Tudor-Locke C, Bassett DR Jr. How many steps/day are enough? Preliminary pedometer indices for public health. *Sports Medicine (Auckland, NZ)*. 2004; 34(1):1–8.
73. Tudor-Locke C, Bassett DR Jr, Rutherford WJ, Ainsworth BE, Chan CB, Croteau K, et al. BMI-referenced cut points for pedometer-determined steps per day in adults. *J Phys Act Health*. 2008;5(Suppl 1):S126–S39.
74. Tudor-Locke C, Burkett L, Reis JP, Ainsworth BE, Macera CA, Wilson DK. How many days of pedometer monitoring predict weekly physical activity in adults? *Prev Med*. 2005;40(3):293–8.
75. Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De Cocker K, Giles-Corti B, et al. How many steps/day are enough? For adults. *The International*

- Journal Of Behavioral Nutrition And Physical Activity. 2011;8:79. <https://doi.org/10.1186/1479-5868-8-79>.
76. Gremeaux V, Drigny J, Nigam A, Juneau M, Guilbeault V, Latour E, et al. Long-term lifestyle intervention with optimized high-intensity interval training improves body composition, cardiometabolic risk, and exercise parameters in patients with abdominal obesity. *American Journal Of Physical Medicine & Rehabilitation*. 2012;91(11):941–50. <https://doi.org/10.1097/PHM.0b013e3182643ce0>.
 77. Seligman BGS, Polanczyk CA, Santos ASB, Foppa M, Junges M, Bonzanini L, et al. Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: a randomized controlled trial. *Metab Clin Exp*. 2011;60(12):1736–40. <https://doi.org/10.1016/j.metabol.2011.05.006>.
 78. Zhang H, Tong TK, Qiu W, Zhang X, Zhou S, Liu Y, et al. Comparable Effects of High-Intensity Interval Training and Prolonged Continuous Exercise Training on Abdominal Visceral Fat Reduction in Obese Young Women. *Journal Of Diabetes Research*. 2017;2017:5071740. <https://doi.org/10.1155/2017/5071740>.
 79. Irving BA, Davis CK, Brock DW, Weltman JY, Swift D, Barrett EJ, et al. Effect of exercise training intensity on abdominal visceral fat and body composition. *Med Sci Sports Exerc*. 2008;40(11):1863–72. <https://doi.org/10.1249/MSS.0b013e3181801d40>.
 80. Giannaki CD, Aghamias G, Sakkis P, Hadjicharalambous M. Eight weeks of a combination of high intensity interval training and conventional training reduce visceral adiposity and improve physical fitness: a group-based intervention. *J Sports Med Phys Fitness*. 2016;56(4):483–90.
 81. Slentz CA, Aiken LB, Houmard JA, Bales CW, Johnson JL, Tanner CJ, et al. Inactivity, exercise, and visceral fat. STRRIDE: a randomized, controlled study of exercise intensity and amount. *J Appl Physiol* (1985). 2005;99(4):1613–8.
 82. Loprinzi PD. Frequency of moderate-to-vigorous physical activity (MVPA) is a greater predictor of systemic inflammation than total weekly volume of MVPA: implications for physical activity promotion. *Physiol Behav*. 2015;141:46–50. <https://doi.org/10.1016/j.physbeh.2015.01.002>.
 83. Cronin O, Keohane DM, Molloy MG, Shanahan F. The effect of exercise interventions on inflammatory biomarkers in healthy, physically inactive subjects: a systematic review. *QJM: Monthly Journal Of The Association Of Physicians*. 2017; <https://doi.org/10.1093/qjmed/hcx091>.
 84. Zdziarski LA, Wasser JG, Vincent HK. Chronic pain management in the obese patient: a focused review of key challenges and potential exercise solutions. *J Pain Res*. 2015;8:63–77. <https://doi.org/10.2147/jpr.s55360>.
 85. Dutheil F, Lac G, Lesourd B, Chapier R, Walthert G, Vinet A, et al. Different modalities of exercise to reduce visceral fat mass and cardiovascular risk in metabolic syndrome: the RESOLVE randomized trial. *Int J Cardiol*. 2013; 168(4):3634–42. <https://doi.org/10.1016/j.ijcard.2013.05.012>.
 86. Loveman E, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. *Health Technol Assess*. 2011;15(2):1–182. <https://doi.org/10.3310/hta15020>.
 87. Annesi JJ, Whitaker AC. Weight loss and psychologic gain in obese women-participants in a supported exercise intervention. *The Permanente Journal*. 2008;12(3):36–45.
 88. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. *Best Pract Res Clin Rheumatol*. 2003; 17(4):685–701. doi:[https://doi.org/10.1016/S1521-6942\(03\)00035-4](https://doi.org/10.1016/S1521-6942(03)00035-4).
 89. Connelly J, Kirk A, Masthoff J, MacRury S. The use of technology to promote physical activity in type 2 diabetes management: a systematic review. *Diabetic Medicine: A Journal Of The British Diabetic Association*. 2013;30(12): 1420–32. <https://doi.org/10.1111/dme.12289>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

